With 3 Key Hires, Mallinckrodt Sets Out Agenda
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharm, spun out of Covidien earlier this year, has rounded out its management team with three key hires from top pharma companies, and reports strong earnings, weaker sales, and aggressive plans for business development as analysts wait for its pipeline to kick in.